SCHEMBL4409899

SCHEMBL4409899

Cc1noc2nc(-c3ccc(F)cc3)c(-c3ccnc(S(C)(=O)=O)n3)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 1/20 0.40
MITF O75030 1/20 0.40
STAT3 P40763 1/20 0.40
STAT1 P42224 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TLR9 Q9NR96 1/20 0.40
PTGS2 P35354 13/20 0.39
PTGS1 P23219 2/20 0.37
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
CCNT1 O60563 2/20 0.35
CDK9 P50750 2/20 0.35
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4407545 0.81 KDM4E (0.38) ALDH1A1LMNAKDM4EMITFSTAT3
SCHEMBL4407549 0.81 MAPK14 (0.48) ALDH1A1LMNASMN1; SMN2GAAMAPT
SCHEMBL4408264 0.76 DYRK1A (0.40) ALDH1A1LMNAGAAMAPTHPGD
SCHEMBL4410198 0.76 PTGS2 (0.43) ALDH1A1LMNAKDM4EMITFSTAT3
SCHEMBL2410945 0.75 RAB9A (0.56) ALDH1A1LMNAKDM4EMITFSTAT3
SCHEMBL4408259 0.74 MAP4K4 (0.50) KDM4EMAPK13MAPK12MAPK11MAPK14
SCHEMBL1384763 0.74 MAP4K4 (0.42) ALDH1A1LMNAKDM4EMITFSTAT3
SCHEMBL4408488 0.73 MAPK13 (0.55) MAPK13MAPK12MAPK11MAPK14
SCHEMBL4408485 0.73 MAPK13 (0.55) MAPK13MAPK12MAPK11MAPK14
SCHEMBL4684079 0.73 PTGS2 (0.46) ALDH1A1LMNAKDM4EMITFSTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US disclosed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US disclosed
EP-1833828-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS Palau Pharma, S.A. (ES) 2007-09-19 EP disclosed
WO-2006013095-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 ALDH1A1 2298/4885LMNA 2258/4885KDM4E 1486/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 ALDH1A1 2298/4885LMNA 2258/4885KDM4E 1486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.